全球肺癌大会2025新药生存期数据领跑,AZ、默沙东、复宏汉霖、百利天恒、康方谁与争锋

MedTrend医趋势
Sep 08, 2025

在9月6日揭幕的2025年世界肺癌大会(WCLC)上,下一代免疫、下一代ADC药物展现出的优异疗效或将颠覆肺癌治疗格局。扩展阅读:一下一代IO+ADC为何颠覆癌症治疗全球顶级药企在实现自我突破。奥希替尼作为全球最畅销的肺癌靶向药物,阿斯利康公布了其联合化疗的最新研究成果。III期临床试验FLAURA2显示,对于既往未经治疗的EGFR突变型晚期NSCLC(非小细胞肺癌)患者,与单独使用奥希替尼相比,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10